Pyrotinib in Women With High-risk in Early Stage Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pyrotinib in Women With High-risk in Early Stage Breast Cancer — Stella

Recruiting

Back to HER2-positive Breast Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Enrollment target

~188 participants

Started

April 2023

Primary completion

June 2026

Age range

18 Years – 75 Years

Sex

Female only

Last updated April 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov